Story preview
BofA Adjusts Price Target on CRISPR Therapeutics to $81 From $82, Keeps Buy Rating
About this story
- Published
- Oct 9, 2026, 2:19 PM UTC
Continue reading on the publisher site for the full article.
Read on publisher →marketscreener.com
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee